Dr. Montanya is raised as the main challenge of the future "to consolidate cyberdem as a reference for the research of excellence in diabetes with a special emphasis on its internationalization."To achieve this, the center will enhance the collaboration between basic and clinical research groups, training activities for young researchers and their visibility both nationally and internationally.
"We also want to intensify relations with other scientific, economic and social agents involved in the field of diabetes, and stimulate that the scientific contribution of CIBERDEM contributes to the improvement of population's health and people with diabetes," says theNew scientific director of CIBERDEM.
Eduard Montanya is a professor at the Faculty of Medicine of the University of Barcelona, head of the Diabetes Section of the University Hospital of Bellvitge and coordinator of the Research Group in Diabetes and Metabolism of the Biomedical Research Institute of Bellvitge (Idibell).
His research has focused on pancreatic islet cells with a particular interest in the function and regeneration of beta cells, responsible for the production of insulin, diabetes cell therapy including the transplant of the islet cells andin new pharmacological treatments of diabetes.He is the author of 150 scientific articles and book chapters.
In addition, Dr. Montanya has advised various leading research institutions at national and international level, and has carried out scientific review in the main scientific societies and magazines in the Diabetes field.The new Cyberdem director won a Fulbright scholarship for a postdoctoral stay in Harvard and has received various awards and research aids.In addition, he has held positions in Spanish, Catalan and international scientific societies.He is currently president of the Advisory Council on Diabetes de Cataluña.
The Network Biomedical Research Center (CIBER) is a consortium under the Carlos III Health Institute (Ministry of Economy and Competitiveness).CIBER in its thematic area of associated diabetes and metabolic diseases (CIBERDEM) is formed by 30 research groups that develop their work since 2007.
